Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,exchangeDataDelayedBy,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,ENTA,436032000,20195100,41506000,,-29155000,,-22045000,8326000,20132000,-29700000,-29700000,,,,,,-7110000,20132000,49832000,0,545000,,-22045000,-22045000,338576000,31735000,436032000,467767000,202000,97199000,994000,55000,1045000,77126000,26618000,345000,55000,14010000,428219000,24493000,298821000,20132000,1479000,5699000,25588000.0,-560000.0,25458000.0,1152000.0,-11000.0,1152000.0,22031000.0,-4579000.0,834000.0,11611000.0,5592000.0,-130000.0,,401601000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,-4.03,-13.976426,21.602,45.79,10.535,0.23007207,48.360943,7.964058,0.16467954,1137489024,-11.287576,2.6073976,15,America/New_York,EDT,-14400000,False,False,56.325,1630508575,-0.875,57.48,57.79,56.325,17215,REGULAR,NMS,2,-1.5297203,56.325 - 57.79,57.2,56.34,56.43,8,22,finmb_345286,NasdaqGS,"Enanta Pharmaceuticals, Inc.",USD,163537,161666,16.005001,0.39694944,40.32 - 57.79,-1.4650002,-0.025350409,40.32,57.79,1620331200,1637578740,1637928000,-3.683,-4.99,0,"Enanta Pharmaceuticals, Inc.",0.41,,,57.79,40.32,45.79,48.36,163.54k,161.67k,20.2M,,14.38M,11.46%,97.76%,1.9M,18.32,11.98%,9.43%,2.03M,,,,,,0.00%,,,,,"Sep 29, 2020","Mar 30, 2021",-78.57%,-89.88%,-10.78%,-16.05%,94.16M,4.69,-27.10%,122.47M,-81.1M,-73.98M,-3.68,,375.95M,18.62,9.3M,2.13,16.09,21.60,-39.42M,-29.75M,Value,02472,Healthcare,141,5,5,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.",Watertown,617 607 0800,MA,10,1609372800,1622505600,3,United States,http://www.enanta.com,86400,7,500 Arsenal Street,617 607 0530,Biotechnology
t-1,ENTA,451995000,20195100,36665000,,-11622000,,-8328000,7377000,31743000,-12299000,-12299000,,,,,,-3294000,31743000,44042000,0,677000,,-8328000,-8328000,332145000,29017000,451995000,481012000,201000,119244000,974000,405000,1045000,55095000,23044000,345000,405000,15563000,445942000,18462000,331101000,31743000,1479000,6305000,-17257000.0,575000.0,-17445000.0,299000.0,-4046000.0,833000.0,-32036000.0,-14890000.0,871000.0,-8251000.0,4289000.0,-188000.0,-534000.0,422898000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,-4.03,-13.976426,21.602,45.79,10.535,0.23007207,48.360943,7.964058,0.16467954,1137489024,-11.287576,2.6073976,15,America/New_York,EDT,-14400000,False,False,56.325,1630508575,-0.875,57.48,57.79,56.325,17215,REGULAR,NMS,2,-1.5297203,56.325 - 57.79,57.2,56.34,56.43,8,22,finmb_345286,NasdaqGS,"Enanta Pharmaceuticals, Inc.",USD,163537,161666,16.005001,0.39694944,40.32 - 57.79,-1.4650002,-0.025350409,40.32,57.79,1620331200,1637578740,1637928000,-3.683,-4.99,0,"Enanta Pharmaceuticals, Inc.",0.41,,,57.79,40.32,45.79,48.36,163.54k,161.67k,20.2M,,14.38M,11.46%,97.76%,1.9M,18.32,11.98%,9.43%,2.03M,,,,,,0.00%,,,,,"Sep 29, 2020","Mar 30, 2021",-78.57%,-89.88%,-10.78%,-16.05%,94.16M,4.69,-27.10%,122.47M,-81.1M,-73.98M,-3.68,,375.95M,18.62,9.3M,2.13,16.09,21.60,-39.42M,-29.75M,Value,02472,Healthcare,141,5,5,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.",Watertown,617 607 0800,MA,10,1609372800,1622505600,3,United States,http://www.enanta.com,86400,7,500 Arsenal Street,617 607 0530,Biotechnology
t-2,ENTA,455580000,20195100,36686000,,-18634000,,-29341000,6728000,23631000,-19783000,-19783000,,,,,,10707000,23631000,43414000,0,1149000,,-29341000,-29341000,326963000,30552000,455580000,486132000,201000,127572000,1078000,844000,1045000,87131000,24157000,345000,844000,15616000,436837000,32634000,299518000,23492000,1479000,5737000,2834000.0,-211000.0,2504000.0,233000.0,-1467000.0,233000.0,-12724000.0,-15461000.0,909000.0,-4839000.0,19488000.0,-330000.0,-534000.0,412680000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,-4.03,-13.976426,21.602,45.79,10.535,0.23007207,48.360943,7.964058,0.16467954,1137489024,-11.287576,2.6073976,15,America/New_York,EDT,-14400000,False,False,56.325,1630508575,-0.875,57.48,57.79,56.325,17215,REGULAR,NMS,2,-1.5297203,56.325 - 57.79,57.2,56.34,56.43,8,22,finmb_345286,NasdaqGS,"Enanta Pharmaceuticals, Inc.",USD,163537,161666,16.005001,0.39694944,40.32 - 57.79,-1.4650002,-0.025350409,40.32,57.79,1620331200,1637578740,1637928000,-3.683,-4.99,0,"Enanta Pharmaceuticals, Inc.",0.41,,,57.79,40.32,45.79,48.36,163.54k,161.67k,20.2M,,14.38M,11.46%,97.76%,1.9M,18.32,11.98%,9.43%,2.03M,,,,,,0.00%,,,,,"Sep 29, 2020","Mar 30, 2021",-78.57%,-89.88%,-10.78%,-16.05%,94.16M,4.69,-27.10%,122.47M,-81.1M,-73.98M,-3.68,,375.95M,18.62,9.3M,2.13,16.09,21.60,-39.42M,-29.75M,Value,02472,Healthcare,141,5,5,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.",Watertown,617 607 0800,MA,10,1609372800,1622505600,3,United States,http://www.enanta.com,86400,7,500 Arsenal Street,617 607 0530,Biotechnology
t-3,ENTA,480557000,20195100,34682000,,-21407000,,-14265000,6823000,18653000,-22852000,-22852000,,,,,,-7142000,18653000,41505000,0,1445000,,-14265000,-14265000,321985000,31147000,480557000,511704000,201000,156913000,1058000,1458000,15989000,99855000,23914000,15289000,1458000,16930000,413381000,65404000,270145000,18653000,1628000,6074000,27052000.0,59000.0,26779000.0,3226000.0,-1313000.0,3226000.0,25517000.0,-4488000.0,916000.0,8966000.0,1149000.0,-273000.0,-534000.0,389467000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,-4.03,-13.976426,21.602,45.79,10.535,0.23007207,48.360943,7.964058,0.16467954,1137489024,-11.287576,2.6073976,15,America/New_York,EDT,-14400000,False,False,56.325,1630508575,-0.875,57.48,57.79,56.325,17215,REGULAR,NMS,2,-1.5297203,56.325 - 57.79,57.2,56.34,56.43,8,22,finmb_345286,NasdaqGS,"Enanta Pharmaceuticals, Inc.",USD,163537,161666,16.005001,0.39694944,40.32 - 57.79,-1.4650002,-0.025350409,40.32,57.79,1620331200,1637578740,1637928000,-3.683,-4.99,0,"Enanta Pharmaceuticals, Inc.",0.41,,,57.79,40.32,45.79,48.36,163.54k,161.67k,20.2M,,14.38M,11.46%,97.76%,1.9M,18.32,11.98%,9.43%,2.03M,,,,,,0.00%,,,,,"Sep 29, 2020","Mar 30, 2021",-78.57%,-89.88%,-10.78%,-16.05%,94.16M,4.69,-27.10%,122.47M,-81.1M,-73.98M,-3.68,,375.95M,18.62,9.3M,2.13,16.09,21.60,-39.42M,-29.75M,Value,02472,Healthcare,141,5,5,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.",Watertown,617 607 0800,MA,10,1609372800,1622505600,3,United States,http://www.enanta.com,86400,7,500 Arsenal Street,617 607 0530,Biotechnology
